stimulation with a physiologically relevant concentration of BLyS did not increase IL-10 + B reg frequency. However, BLyS stimulation did increase the frequency of the overall B cell compartment and promoted B cell proliferation upon B cell receptor engagement. Therefore, using BLyS as an adjuvant with therapeutic peptide vaccination could promote humoral immunity with no increase in immunosuppressive IL-10 + B regs . These results have implications for modulating humoral responses in human peptide vaccine trials in patients with GBM. (BLyS) is a key regulatory molecule in IL-10 + B reg biology with tightly controlled serum levels. However, BLyS levels can be drastically altered upon chemotherapeutic intervention. We have previously shown that serum BLyS levels are elevated, and directly associated, with increased antigen-specific antibody titers in patients with glioblastoma (GBM) undergoing lymphodepletive temozolomide chemotherapy and vaccination. In this study, we examined corresponding IL-10 + B reg responses within this patient population and demonstrate that the IL-10 + B reg compartment remains constant before and after administration of the vaccine, despite elevated BLyS levels in circulation. IL-10 + B reg frequencies were not associated with serum BLyS levels, and ex vivo Anirudh Saraswathula and Elizabeth A. Reap have contributed equally to this work.
B regs ) represent a suppressive subset of the B cell compartment with prominent anti-inflammatory capacity, capable of suppressing cellular and humoral responses to cancer and vaccines. B lymphocyte stimulator (BLyS) is a key regulatory molecule in IL-10 + B reg biology with tightly controlled serum levels. However, BLyS levels can be drastically altered upon chemotherapeutic intervention. We have previously shown that serum BLyS levels are elevated, and directly associated, with increased antigen-specific antibody titers in patients with glioblastoma (GBM) undergoing lymphodepletive temozolomide chemotherapy and vaccination. In this study, we examined corresponding IL-10 + B reg responses within this patient population and demonstrate that the IL-10 + B reg compartment remains constant before and after administration of the vaccine, despite elevated BLyS levels in circulation. IL-10 + B reg frequencies were not associated with serum BLyS levels, and ex vivo Anirudh Saraswathula and Elizabeth A. Reap have contributed equally to this work.
Introduction

Regulatory B cells (IL-10
+ B regs ) play an immunosuppressive role in mouse models for autoimmunity and cancer [1] [2] [3] [4] [5] . + B regs downregulate effector T cell responses through the secretion of immunosuppressive cytokines such as interleukin-10 (IL-10) and through cell-to-cell contact [1, 4, 6] and have been shown to promote cancer progression in murine models by upregulating immunosuppressive cell subsets such as regulatory T cells (T regs ) [7] . However, the regulation of these cells, especially in human systems, is not well understood [8, 9] . B lymphocyte stimulator (BLyS) is a B cell homeostatic cytokine that promotes differentiation and survival of B cells and has been linked to the promotion of IL-10 + B regs in preclinical and clinical studies [10] [11] [12] [13] . Examination of BLyS and IL-10 + B regs in the context of vaccination may provide important information on the induction of potentially immunosuppressive and detrimental IL-10 + B regs responses. Our phase II trial of rindopepimut ® , an epidermal growth factor receptor variant III (EGFRvIII) vaccine consisting of a 14-amino acid peptide containing the EGFRvIII mutation (PEPvIII, H-Leu-Glu-Glu-Lys-Lys-Gln-AsnTyr-Val-Val-Thr-Asp-His-Cys-OH) chemically conjugated to keyhole limpet hemocyanin (KLH) for the treatment of patients with glioblastoma (GBM) has shown a survival benefit in a multicenter, single-arm phase II clinical trial (ACT-III) [14] , likely through an antibody-dependent mechanism. In newly diagnosed patients with GBM, this vaccine was administered with the standard-of-care (SOC) lymphodepleting chemotherapeutic alkylating agent temozolomide (TMZ) and these patients developed supraphysiological EGFRvIII-specific antibody titers [15] [16] [17] [18] . Further analysis revealed elevated serum BLyS levels (likely due to the lymphodepletive effects of TMZ), and these BLyS levels directly correlated with vaccine-induced immunoglobulin levels [19] . This clinical observation is supported by preclinical studies demonstrating a role for BLyS in the promotion of humoral responses [20, 21] .
In this study, we examine the association of human IL-10 + B regs with serum BLyS levels in the context of SOC TMZ treatment and PEPvIII-KLH vaccination in patients with GBM [22] [23] [24] . Since BLyS levels are elevated in the context of TMZ-induced lymphopenia, we hypothesized that BLyS stimulation may enhance IL-10 + B regs frequencies in these patients and impede the ability to achieve maximal anti-tumor immune responses [19, 25, 26] 
Materials and methods
Patient samples
Cryopreserved patient samples were collected by blood draw or leukapheresis from the ACT-II trial, as described in [15] . Briefly, adults with newly diagnosed GBM who had gross total resection of their EGFRvIII-positive tumor and a Karnofsky performance status (KPS) score of ≥80 with no radiographic evidence of progression after radiation therapy were eligible for vaccination. The trial design and informed consent were approved by the FDA (under BB-IND-9944) and the local institutional review boards [15] [16] [17] . After tumor resection and conformal external beam radiotherapy (XRT) with concurrent TMZ at a targeted dose of 75 mg/m 2 , informed consent was obtained. The initial 3 vaccinations of a 14-mer peptide conjugated to KLH were given every two weeks starting within 6 weeks of completing radiation [15, 16] . Subsequent vaccines were given until clinical or radiographic evidence of tumor progression or death. Patients were assigned to receive TMZ at a targeted dose of 100 mg/m 2 for the first 21 days of a 28-day cycle (n = 8).
Patient samples selected for analyses were taken at vaccine 1, prior to any vaccination or TMZ treatment at 100 mg/m 2 (Pre), and at a patient variable post-vaccination time point that was selected to occur after patient peak serum BLyS levels and near peak anti-EGFRvIII antibody titers (post) [19] . Table 1 includes the serum BLyS levels of GBM patients at the time of IL-10 + B reg analysis. These time points were selected based on our hypothesis that serum BLyS elevation will directly translate into an enhancement of IL-10 + B reg frequency, and based on our available clinical samples. Normal donor samples were collected at Duke University Medical Center.
Ex vivo evaluation of IL-10 competency
In accordance with the protocols adopted from Iwata et al. [8] , and with the studies from Khoder et al. [9] , peripheral blood mononuclear cells (PBMCs) were utilized for these studies because of the limited clinical sample availability. PBMCs were rested overnight (o/n) in RPMI Medium 1640 with GlutaMAX™-I (Gibco) plus 10 % fetal bovine serum (FBS, GemCell™). Cells were then harvested and plated at 4.0 × 10 6 cells/ml in 48-well plate for 43 h in media supplemented with 1 µg/ml CD40L (R&D Systems) and 10 µg/ml lipopolysaccharide (LPS, Sigma-Aldrich catalog no. L4391). They were subsequently stimulated for 5 h with 50 ng/ml phorbol myristate acetate (PMA, SigmaAldrich), 1 µg/ml ionomycin (Sigma-Aldrich), 10 µg/ml LPS, and 1ul/ml of Brefeldin A (BFA, BD Biosciences GolgiPlug™-Protein Transport Inhibitor).
Cells were washed and stained with monoclonal fluorophore-conjugated antibodies for the following cell surface markers: extracellular peridinin chlorophyll protein complex (PerCP)-anti-CD19 and fluorescein isothiocyanate (FITC)-anti-CD14 as well as intracellular Allophycocyanin (APC)-anti-IL-10. Intracellular staining was performed using the Cytofix/Cytoperm™ Kit (BD Biosciences) as described by manufacturer.
Ex vivo BLyS-sensitivity assay
In order to examine cell sensitivity to BLyS, cells were stimulated in a similar protocol as used for the determination of IL-10 competency. BLyS (2000 ng/ml; B cellactivating factor (BAFF), R&D Systems) was added to the initial stimulation media as described above, and 4.0 × 10 6 cells/ml rested PBMCs were stimulated for 67 h in a 48-well plate before being transferred for 5 h to media containing 50 ng/ml PMA (Sigma-Aldrich), 1 µg/ml ionomycin (Sigma-Aldrich), 10 µg/ml LPS (Sigma-Aldrich), and 1 ul/ml of BFA (BD Biosciences). The intracellular staining was performed identically as described above.
B cell proliferation assay
To assess the B cell proliferative response to BLyS stimulation, we stained normal donor PBMCs with carboxyfluorescein succinimidyl ester (CFSE, Life Technologies), a fluorescent stain used to track cell proliferation, and stimulated with goat anti-immunoglobulin (Ig)M (Southern Biotech) and BLyS (R&D; 2000 ng/ml) in a 48-well plate (BD Falcon) for 72 h. The cells were then stained for CD19 (PerCP) and analyzed for proliferation by flow cytometry.
Statistical analysis
Based on previous studies demonstrating the impact of BLyS on increasing the IL-10 + B reg frequency among B cells [10] [11] [12] [13] , our a priori hypothesis was that due to the elevated serum BLyS levels experienced in our GBM patient population [19] , this effect will directly translate into an enhancement of IL-10 + B reg frequency within the B cells compartment. Since this hypothesis is unidirectional, a paired, one-tailed Student's t test was used to compare IL-10 + B regs frequency in pre-and post-vaccination samples. A Pearson linear regression was used to assess associations and statistical significance when examining associations with various other trial parameters. An unpaired, one-tailed Student's t test was used when comparing BLySinduced IL-10 + B regs frequencies in GBM patients to normal donor samples. Statistical significance was defined at p < 0.05. All statistical analysis was completed in GraphPad Prism 5.00.
Results
The frequency of IL-10
+ B regs is unchanged following TMZ and peptide vaccine treatment
To understand the effect of tumor-specific peptide vaccination and TMZ-induced lymphopenia, on IL-10-secreting IL-10 + B regs and based on the hypothesis that serum BLyS elevation will directly translate into an enhancement of IL-10 + B reg frequency, we examined PBMCs from cryopreserved samples from PEPvIII-KLH-vaccinated GBM patients undergoing lymphodepletive TMZ treatment, utilizing a functional IL-10 + B reg assay adopted from Iwata et al. [8] and Khoder et al. [9] depicted in Fig. 1a , b. IL-10 + B reg frequency was analyzed at vaccine 1, prior to any vaccination or TMZ treatment at 100 mg/m 2 (Pre), and was also analyzed post-vaccination at a time point chosen on a patient by patient basis that was selected to occur after peak serum BLyS levels and near peak antiEGFRvIII antibody titers (post) [19] . Table 1 includes the serum BLyS levels of GBM patients at the time of IL-10 + B reg analysis. In accordance with previous studies published from this patient population [15] , analysis of the B cell population demonstrated an expected reduction in the frequency of B cells ( Fig. 1c ; *p = 0.0466). This reduction is largely attributed to the lymphodepletive effect of TMZ chemotherapy [15] . Of interest, while the B cell frequency was reduced, there was no significant difference in IL-10 + B reg frequency between these time points (Fig. 1d) .
The frequency of IL-10 + B regs does not associate with anti-EGFRvIII antibody titers or patient survival
Published data indicate a potential role for IL-10 + B reg in regulating humoral and cellular responses to vaccines as well as a regulatory role in immunosuppression and cancer progression. We therefore decided to analyze the relationship of IL-10 + B reg frequency with peak anti-EGFRvIII antibody titers and patient survival outcomes. We found that post-vaccination IL-10 + B reg frequency is not related to peak anti-EGFRvIII antibody titers ( Fig. 2a; r 2 = 0.03185; p = 0.6724). Also, there does not appear to be any association with overall patient survival ( Fig. 2b ; r 2 = 0.06793; p = 0.5330) progression-free survival, or time to radiographic progression of disease ( Fig. 2c ; r 2 = 0.09114; p = 0.4674) measured in months (mo). Fig. 1 IL-10 + B regs frequency remains constant in glioblastoma patients undergoing TMZ and peptide vaccine. a PBMCs were rested overnight (o/n) in media (RPMI Medium 1640 with GlutaMAX™-I plus 10 % FBS). Cells were harvested and stimulated in a 48-well plate at 4.0 × 10 6 cells/ml for 43 h in media supplemented with 1 µg/ ml CD40L and 10 µg/ml LPS. They were subsequently stimulated for 5 h in media with 50 ng/ml PMA, 1 µg/ml ionomycin, 10 µg/ ml LPS, and 1× Brefeldin A (BFA) before being stained for CD19, CD14, IL-10, and, in some experiments, the EGFRvIII tetramer. b A representative flow cytometry sample from a patient sample is shown, compared to the appropriate negative control. c In the same experiments, the frequency of total B cells was found to decrease over the course of vaccination (*p = 0.0466). 
B regs but increases the frequency and proliferation of B cells
Since previous preclinical studies have demonstrated a role for BLyS in promoting IL-10 + B reg frequencies, we decided to evaluate whether BLyS serum levels were associated with IL-10 + B reg frequencies in our GBM patients at time of IL-10 + B reg analysis (Table 1) . Therefore, we compared IL-10 + B reg frequencies to corresponding patient BLyS serum levels. There was no significant association (Fig. 3a , R 2 = 0.3253; p = 0.1399) between IL-10 + B reg and patient BLyS serum levels. Since our previous findings suggested a strong relationship between serum BLyS and B cell activity [19] , we investigated these seemingly incongruous results by stimulating healthy, normal donor PBMC samples with BLyS in addition to ex vivo B cell receptor stimulation before intracellular IL-10 staining. We found no significant difference in IL-10 + B reg frequency when cells were cultured with physiologically relevant levels of BLyS ( Fig. 3b ; p = 0.4882). However, both the frequency of B cells ( Fig. 3c ; *p = 0.0283) and the level of proliferation as determined by carboxyfluorescein succinimidyl ester (CFSE) did increase significantly ( Fig. 3d ; *p = 0.0284). Thus, BLyS does not appear to affect the IL-10 + B reg compartment in ex vivo samples at the time of peak antibody titer or in vitro healthy donor samples, but does increase global B cell frequency and proliferation.
Discussion
In the context of tumor-specific vaccination during lymphodepletive TMZ chemotherapy in patients with GBM, we found that IL-10 + B reg frequency was unchanged despite elevated BLyS levels at the time of analysis. While this therapy elicits robust production of anti-EGFRvIII antibodies and results in an increased overall survival when compared to historical controls [14, 15, 24] , IL-10 + B reg frequency was not associated with peak anti-EGFRvIII antibody titers, patient survival outcomes, or BLyS levels. These results were unexpected due the mouse and human literature demonstrating a link between BLyS levels and IL-10 + B reg promotion [10] [11] [12] . However, recent studies suggest that IL-10 + B reg subsets may not have the same activation-program response to BLyS observed in the greater CD19 + B cell compartment [27] , which could account for the IL-10 + B reg dynamics observed in our study. Another important point is the utilization of rested PBMCs for the IL-10 + B reg assay. Many studies utilize purified B cells in stimulation assays in order to specifically stimulate the pure B cell population and to determine the IL-10 + B reg fraction [8, 28] . As we utilized PBMCs, there is the possibility of an indirect B cell stimulation by factors secreted by non-B cell subsets which might contribute to IL-10 + B reg differentiation. Caveats of this study are the limited availability of the clinical samples as well as the decreased lymphocyte counts within these samples due to patient treatment with lymphodepletive TMZ chemotherapy. However, a recent study by Khoder et al. [9] demonstrated that IL-10 + B regs can be effectively examined from whole PBMCs. Therefore, we believe that our results represent the normal physiology of the IL-10 + B reg compartment and that this compartment is not increased under elevated levels of serum BLyS.
IL-10 + B regs represent a suppressive compartment of the B cell lineage. While several markers exist to identify different B reg subsets in humans, the reported phenotype of these cells varies between studies [8, 28, 29] . A B cell high has been shown to secrete large amounts of IL-10 upon stimulation through CD40 [28] . Another human B reg cell subset equivalent to murine B10 cells, which expresses CD24 and the memory-related marker CD27 [8, 30] , has also been identified. While different subsets exist for IL-10 + B regs in both humans and mice, the IL-10 + B reg subset evaluated in this study universally displays the phenotypic markers of CD19 + CD24 high CD38
high . Therefore, our study focuses on the evaluation of CD19 + CD24 high CD38 high IL-10 + B regs , which are largely considered to be the main contributors of IL-10 secretion and regulation. Our study demonstrates that this population might not be as sensitive to the homeostatic cytokine BLyS as previously expected from studies that demonstrate the role of BLyS on IL-10 + B reg homeostasis. It remains to be elucidated whether another distinct regulatory B cell subset characterized by CD1d high CD5 + expression, which was previously determined to be sensitive to BLyS-induced expansion [10] [11] [12] [13] , will be elevated in these patients with elevated serum BLyS levels.
These data indicate that in the context of TMZ-induced lymphopenia and humoral immunity-targeting vaccines, IL-10 + B regs may not be as responsive to BLyS as nonregulatory B cell subsets. These discrepancies may pertain to differences in BLyS receptor expression or the expression of intracellular adaptor molecules known to regulate receptor-mediated IL-10 induction [13] . Alternatively, in response to BLyS, serial vaccinations with PEPvIII-KLHinducing anti-EGFRvIII immunoglobulins may differentially affect activation and maturation between regulatory and nonregulatory B cell subsets. Unlike the T reg compartment [31] [32] [33] [34] , our current and previous findings [19] indicate that there may be diminished IL-10 + B reg responses to tumor-specific vaccines.
These results have implications for interpreting and more effectively modulating humoral responses in human peptide vaccine trials. By delineating the interplay between BLyS, IL-10 + B regs , and antigen-specific humoral responses, we may ultimately be able to deliver tangible benefits for patients with refractory tumors (i.e., GBM) expressing tumor-specific surface antigens. Importantly, our findings indicate that IL-10 + B regs may not be a regulatory barrier in the use of BLyS as a humoral adjuvant for vaccine-based cancer immunotherapy.
